Clinical, hematologic, and cytogenetic characteristics of MDS patients with trisomy 8
| Patient no. . | Sex/ age, y . | FAB . | BM blasts, % . | Hemoglobin level, g/L . | WBC count, 109/L . | Platelet count, 109/L . | Karyotype . | Treatment . | |
|---|---|---|---|---|---|---|---|---|---|
| Ongoing . | Previous . | ||||||||
| 1 | M/62 | RA | < 5 | 133 | 6,1 | 8 | 47,XY,+8[8]/46,XY[17] | — | — |
| 2 | M/84 | RA | < 5 | 59 | 11,0 | 206 | 47,XY,+8[6]/47,idem,del(17)(p?)[4] | — | — |
| 3 | M/80 | RA | < 5 | 89 | 3,0 | 206 | 47,XY,del(5)(q?),+8[1]/46,XY[12] | — | — |
| 4 | M/74 | CMML | < 5 | 83 | 145,5 | 77 | 46-47,XY,+8[8]/47,idem,del(17)(p?)[4] | — | — |
| 5 | F/66 | RARS | < 5 | 80 | 3,0 | 85 | 45-48,XX,−4,del(5)(q?),del(7)(q?),+8,−16,−17, del(19)+1-6mar[33]/46,XX[2] | — | — |
| 6 | F/78 | RAEB | 10 | 100 | 3,0 | 100 | 47,XX,+8[27] | — | CT* |
| 7 | F/62 | RAEB | 10 | 65 | 7,7 | 211 | 47,XX,+8[5]/46,XX[5] | — | — |
| 8 | F/59 | RAEB | 10 | 75 | 4,4 | 20 | 50,XX,+8,+9,+14,+21[26] | IT† | — |
| 9 | F/73 | CMML | 12 | 48 | 80,8 | 105 | 47,XX,+8[4]/47,idem,del(17)(p?)[5] | — | Pred |
| 10 | F/74 | RAEB | 17 | 91 | 8,9 | 128 | 42-46,XX,del(5)(q22)[24]/47,XX,del(5)(q22),+8[1] | Pred | — |
| 11 | M/73 | RAEBt | 20 | 48 | 7,1 | 341 | 47,XY,+8[4]/46,XY[2] | — | — |
| 12 | M/51 | RAEBt | 25 | 51 | 4,3 | 71 | 45-47,XY,−5,del(7)(q22),+8,del(20)(q11.2),+20[7] | — | — |
| 13 | F/79 | MDS-AML‡ | 35 | 87 | 19,6 | 21 | 44,XX,−3,del(5)(q?),+8,−12,−13,−14,−15,−16[42] | — | — |
| Patient no. . | Sex/ age, y . | FAB . | BM blasts, % . | Hemoglobin level, g/L . | WBC count, 109/L . | Platelet count, 109/L . | Karyotype . | Treatment . | |
|---|---|---|---|---|---|---|---|---|---|
| Ongoing . | Previous . | ||||||||
| 1 | M/62 | RA | < 5 | 133 | 6,1 | 8 | 47,XY,+8[8]/46,XY[17] | — | — |
| 2 | M/84 | RA | < 5 | 59 | 11,0 | 206 | 47,XY,+8[6]/47,idem,del(17)(p?)[4] | — | — |
| 3 | M/80 | RA | < 5 | 89 | 3,0 | 206 | 47,XY,del(5)(q?),+8[1]/46,XY[12] | — | — |
| 4 | M/74 | CMML | < 5 | 83 | 145,5 | 77 | 46-47,XY,+8[8]/47,idem,del(17)(p?)[4] | — | — |
| 5 | F/66 | RARS | < 5 | 80 | 3,0 | 85 | 45-48,XX,−4,del(5)(q?),del(7)(q?),+8,−16,−17, del(19)+1-6mar[33]/46,XX[2] | — | — |
| 6 | F/78 | RAEB | 10 | 100 | 3,0 | 100 | 47,XX,+8[27] | — | CT* |
| 7 | F/62 | RAEB | 10 | 65 | 7,7 | 211 | 47,XX,+8[5]/46,XX[5] | — | — |
| 8 | F/59 | RAEB | 10 | 75 | 4,4 | 20 | 50,XX,+8,+9,+14,+21[26] | IT† | — |
| 9 | F/73 | CMML | 12 | 48 | 80,8 | 105 | 47,XX,+8[4]/47,idem,del(17)(p?)[5] | — | Pred |
| 10 | F/74 | RAEB | 17 | 91 | 8,9 | 128 | 42-46,XX,del(5)(q22)[24]/47,XX,del(5)(q22),+8[1] | Pred | — |
| 11 | M/73 | RAEBt | 20 | 48 | 7,1 | 341 | 47,XY,+8[4]/46,XY[2] | — | — |
| 12 | M/51 | RAEBt | 25 | 51 | 4,3 | 71 | 45-47,XY,−5,del(7)(q22),+8,del(20)(q11.2),+20[7] | — | — |
| 13 | F/79 | MDS-AML‡ | 35 | 87 | 19,6 | 21 | 44,XX,−3,del(5)(q?),+8,−12,−13,−14,−15,−16[42] | — | — |
BM morphology and blood values of the patients were investigated in connection with BM aspirations for the present studies. Karyotypes were established on whole BM by metaphase analysis.
MDS indicates myelodysplastic syndromes; FAB, French-American-British classification; BM, bone marrow; RA, refractory anemia; RARS, refractory anemia with ringsideroblasts; RAEB, refractory anemia with excess of blasts; RAEBt, refractory anemia with excess of blasts in transformation; CMML, chronic myelo-monocytic leukemia; CT, chemotherapy; IT, immune therapy; and Pred, prednisolone.
Mitoxantrone + etoposide + arabinosylcytosine, 2 years prior to this study.
Antithymocyte-globuline + cyclosporin A + prednisolone.
Tri-lineage dysplasia.